Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

finance.yahoo.com · 2026-08-31

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-w

Read the full story at finance.yahoo.com →